CA2385737A1 - Piperazine derivatives as 5-ht1b antagonists - Google Patents
Piperazine derivatives as 5-ht1b antagonists Download PDFInfo
- Publication number
- CA2385737A1 CA2385737A1 CA002385737A CA2385737A CA2385737A1 CA 2385737 A1 CA2385737 A1 CA 2385737A1 CA 002385737 A CA002385737 A CA 002385737A CA 2385737 A CA2385737 A CA 2385737A CA 2385737 A1 CA2385737 A1 CA 2385737A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- cis
- compound
- 6alkyl
- trimethylpiperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000005557 antagonist Substances 0.000 title claims abstract description 8
- 150000004885 piperazines Chemical class 0.000 title abstract description 5
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 59
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 139
- -1 COC1-6alkyl Chemical group 0.000 claims description 85
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 85
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 13
- 125000001624 naphthyl group Chemical group 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical group CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 101100477978 Hypocrea jecorina (strain QM6a) sor6 gene Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 105
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 58
- 239000000203 mixture Substances 0.000 description 50
- 239000007787 solid Substances 0.000 description 47
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- NXORPZCTEJPGLK-UHFFFAOYSA-N 1-(3,4,5-trimethylpiperazin-1-yl)-2,3-dihydroindole Chemical compound C1C(C)N(C)C(C)CN1N1C2=CC=CC=C2CC1 NXORPZCTEJPGLK-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 229910052786 argon Inorganic materials 0.000 description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- 239000000284 extract Substances 0.000 description 14
- 239000003921 oil Substances 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- KXQDURQOOILBOU-UHFFFAOYSA-N 2-(3,4,5-trimethylpiperazin-1-yl)-1h-indole Chemical compound C1C(C)N(C)C(C)CN1C1=CC2=CC=CC=C2N1 KXQDURQOOILBOU-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 238000002825 functional assay Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 5
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- MALRPHGBZAYUJS-UHFFFAOYSA-N 1-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)-2,3-dihydroindole Chemical compound C1=C2N(OC)CCC2=CC=C1N1CC(C)N(C)C(C)C1 MALRPHGBZAYUJS-UHFFFAOYSA-N 0.000 description 4
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- BNPHYNQCHNBJEL-TXEJJXNPSA-N (2s,6r)-1-benzyl-2,6-dimethylpiperazine Chemical compound C[C@H]1CNC[C@@H](C)N1CC1=CC=CC=C1 BNPHYNQCHNBJEL-TXEJJXNPSA-N 0.000 description 3
- AFBOHIVNJUEYQE-UHFFFAOYSA-N 1-(5-hydroxy-3,3-dimethyl-2h-indol-1-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)CC(C)(C)C2=C1 AFBOHIVNJUEYQE-UHFFFAOYSA-N 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- KUCBRCVQLSSGOU-UHFFFAOYSA-N (1-acetyl-3,3-dimethyl-2h-indol-5-yl) acetate Chemical compound CC(=O)OC1=CC=C2N(C(C)=O)CC(C)(C)C2=C1 KUCBRCVQLSSGOU-UHFFFAOYSA-N 0.000 description 2
- IFNWESYYDINUHV-OLQVQODUSA-N (2s,6r)-2,6-dimethylpiperazine Chemical compound C[C@H]1CNC[C@@H](C)N1 IFNWESYYDINUHV-OLQVQODUSA-N 0.000 description 2
- KBHGTTWVFRLPRO-UHFFFAOYSA-N (4-formylnaphthalen-1-yl)boronic acid Chemical compound C1=CC=C2C(B(O)O)=CC=C(C=O)C2=C1 KBHGTTWVFRLPRO-UHFFFAOYSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NWGUGRZILRRSSH-UHFFFAOYSA-N 1-(1-acetyl-3,3-dimethyl-2h-indol-5-yl)ethanone Chemical compound CC(=O)C1=CC=C2N(C(=O)C)CC(C)(C)C2=C1 NWGUGRZILRRSSH-UHFFFAOYSA-N 0.000 description 2
- UJTAWOIWCRBJTH-UHFFFAOYSA-N 1-(5-methoxy-3,3-dimethyl-2h-indol-1-yl)ethanone Chemical compound COC1=CC=C2N(C(C)=O)CC(C)(C)C2=C1 UJTAWOIWCRBJTH-UHFFFAOYSA-N 0.000 description 2
- OCEAQMQNNWWZRH-UHFFFAOYSA-N 1-(6-bromo-5-methoxy-2,3-dihydroindol-1-yl)ethanone Chemical compound C1=C(Br)C(OC)=CC2=C1N(C(C)=O)CC2 OCEAQMQNNWWZRH-UHFFFAOYSA-N 0.000 description 2
- FNGNMVLKSLYRQV-UHFFFAOYSA-N 1-(6-bromo-5-methoxy-3,3-dimethyl-2h-indol-1-yl)ethanone Chemical compound C1=C(Br)C(OC)=CC2=C1N(C(C)=O)CC2(C)C FNGNMVLKSLYRQV-UHFFFAOYSA-N 0.000 description 2
- VKCXDTZTJVJKCC-UHFFFAOYSA-N 1-methyl-6-(3,4,5-trimethylpiperazin-1-yl)-2,3-dihydroindole Chemical compound C1C(C)N(C)C(C)CN1C1=CC=C(CCN2C)C2=C1 VKCXDTZTJVJKCC-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- KCKUPSFGTHKWRY-IYBDPMFKSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]-1-[5-methoxy-6-[(3r,5s)-3,4,5-trimethylpiperazin-1-yl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C1=2C=C(N3C[C@@H](C)N(C)[C@@H](C)C3)C(OC)=CC=2CCN1C(=O)CC1=CC=CC(C(F)(F)F)=C1F KCKUPSFGTHKWRY-IYBDPMFKSA-N 0.000 description 2
- IDMMCNXCUQZGAG-UHFFFAOYSA-N 2-[4-(6-methylpyridin-2-yl)naphthalen-1-yl]acetic acid Chemical compound CC1=CC=CC(C=2C3=CC=CC=C3C(CC(O)=O)=CC=2)=N1 IDMMCNXCUQZGAG-UHFFFAOYSA-N 0.000 description 2
- SOHDPICLICFSOP-UHFFFAOYSA-N 2-bromo-6-methylpyridine Chemical compound CC1=CC=CC(Br)=N1 SOHDPICLICFSOP-UHFFFAOYSA-N 0.000 description 2
- QWSRIRITNXYEJV-UHFFFAOYSA-N 4-(1-methyl-6-oxopyridin-3-yl)naphthalene-1-carboxylic acid Chemical compound C1=CC(=O)N(C)C=C1C1=CC=C(C(O)=O)C2=CC=CC=C12 QWSRIRITNXYEJV-UHFFFAOYSA-N 0.000 description 2
- PMMSIFYTAUIBPK-UHFFFAOYSA-N 4-(2,6-dimethylpyridin-3-yl)naphthalene-1-carboxylic acid Chemical compound CC1=NC(C)=CC=C1C1=CC=C(C(O)=O)C2=CC=CC=C12 PMMSIFYTAUIBPK-UHFFFAOYSA-N 0.000 description 2
- GULXIJUDPRAQPG-UHFFFAOYSA-N 4-(3,6-dimethylpyrazin-2-yl)naphthalene-1-carboxylic acid Chemical compound CC1=CN=C(C)C(C=2C3=CC=CC=C3C(C(O)=O)=CC=2)=N1 GULXIJUDPRAQPG-UHFFFAOYSA-N 0.000 description 2
- MJHAKCHFCZJBGL-UHFFFAOYSA-N 4-(6-methylpyridin-2-yl)naphthalene-1-carboxylic acid Chemical compound CC1=CC=CC(C=2C3=CC=CC=C3C(C(O)=O)=CC=2)=N1 MJHAKCHFCZJBGL-UHFFFAOYSA-N 0.000 description 2
- SUOJTAAZMOESCE-UHFFFAOYSA-N 4-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]naphthalene-1-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CC=C(C(O)=O)C2=CC=CC=C12 SUOJTAAZMOESCE-UHFFFAOYSA-N 0.000 description 2
- SRYYKYNBMCQCAB-UHFFFAOYSA-N 4-borononaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(B(O)O)=CC=C(C(O)=O)C2=C1 SRYYKYNBMCQCAB-UHFFFAOYSA-N 0.000 description 2
- ZJPCJZIXHSJCOZ-UHFFFAOYSA-N 7-(3,4,5-trimethylpiperazin-1-yl)-1,2,3,4-tetrahydroquinoline Chemical compound C1C(C)N(C)C(C)CN1C1=CC=C(CCCN2)C2=C1 ZJPCJZIXHSJCOZ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NHEPTUFVZYXJFY-UHFFFAOYSA-N CC=1C(=C(C(=C2CCNC=12)C)OC)N1CC(N(C(C1)C)C)C Chemical compound CC=1C(=C(C(=C2CCNC=12)C)OC)N1CC(N(C(C1)C)C)C NHEPTUFVZYXJFY-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 101150050738 HTR1B gene Proteins 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Chemical group 0.000 description 2
- 101100321769 Takifugu rubripes htr1d gene Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- VTQSIRZSABRYHH-SZPZYZBQSA-N [6-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-5-methoxy-2,3-dihydroindol-1-yl]-[4-(6-methylpyridin-2-yl)naphthalen-1-yl]methanone Chemical compound C1=2C=C(N3C[C@@H](C)N[C@@H](C)C3)C(OC)=CC=2CCN1C(=O)C(C1=CC=CC=C11)=CC=C1C1=CC=CC(C)=N1 VTQSIRZSABRYHH-SZPZYZBQSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- ANWDMUUOVHKSHJ-UHFFFAOYSA-N methyl 2-(4-trimethylstannylnaphthalen-1-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OC)=CC=C([Sn](C)(C)C)C2=C1 ANWDMUUOVHKSHJ-UHFFFAOYSA-N 0.000 description 2
- LAIMYDJZXYZPQY-UHFFFAOYSA-N methyl 4-(1-methylpiperidin-4-yl)naphthalene-1-carboxylate Chemical compound C12=CC=CC=C2C(C(=O)OC)=CC=C1C1CCN(C)CC1 LAIMYDJZXYZPQY-UHFFFAOYSA-N 0.000 description 2
- UXFZIKWMJJQRIJ-UHFFFAOYSA-N methyl 4-piperidin-4-ylnaphthalene-1-carboxylate Chemical compound C12=CC=CC=C2C(C(=O)OC)=CC=C1C1CCNCC1 UXFZIKWMJJQRIJ-UHFFFAOYSA-N 0.000 description 2
- WJBSUJNHKVSYAW-UHFFFAOYSA-N methyl 4-trimethylstannylnaphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC=C([Sn](C)(C)C)C2=C1 WJBSUJNHKVSYAW-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000003653 radioligand binding assay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000004001 serotonin 1D antagonist Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QHVYJSBQXIIROJ-KNVOCYPGSA-N (2s,6r)-1,2,6-trimethylpiperazine Chemical compound C[C@H]1CNC[C@@H](C)N1C QHVYJSBQXIIROJ-KNVOCYPGSA-N 0.000 description 1
- FYWJWWMKCARWQG-UHFFFAOYSA-N 1,2-dichloro-3-isocyanatobenzene Chemical compound ClC1=CC=CC(N=C=O)=C1Cl FYWJWWMKCARWQG-UHFFFAOYSA-N 0.000 description 1
- BDKDQGYCFLQERH-UHFFFAOYSA-N 1-(6-bromo-2,3-dihydroindol-1-yl)ethanone Chemical compound C1=C(Br)C=C2N(C(=O)C)CCC2=C1 BDKDQGYCFLQERH-UHFFFAOYSA-N 0.000 description 1
- YYLCTJPPMXSFDP-UHFFFAOYSA-N 1-(6-bromo-5-fluoro-2,3-dihydroindol-1-yl)ethanone Chemical compound FC1=C(Br)C=C2N(C(=O)C)CCC2=C1 YYLCTJPPMXSFDP-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- JZEWYZAIWWNAPZ-UHFFFAOYSA-N 2-[2-chloro-3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(F)(F)F)=C1Cl JZEWYZAIWWNAPZ-UHFFFAOYSA-N 0.000 description 1
- IZXLNEHPKQVCAE-UHFFFAOYSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(F)(F)F)=C1F IZXLNEHPKQVCAE-UHFFFAOYSA-N 0.000 description 1
- BGXZMBZFGAIBDH-UHFFFAOYSA-N 2-chloro-3-(trifluoromethyl)phenol Chemical compound OC1=CC=CC(C(F)(F)F)=C1Cl BGXZMBZFGAIBDH-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IWGRDSKHXRMTDE-UHFFFAOYSA-N 3-bromo-2,6-dimethylpyridine;hydrochloride Chemical compound Cl.CC1=CC=C(Br)C(C)=N1 IWGRDSKHXRMTDE-UHFFFAOYSA-N 0.000 description 1
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
- NNBALVIZMGWZHS-UHFFFAOYSA-N 3-chloro-2,5-dimethylpyrazine Chemical compound CC1=CN=C(C)C(Cl)=N1 NNBALVIZMGWZHS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CGPIONYVXKQZPW-UHFFFAOYSA-N 4-bromo-2,5-dimethylpyridine Chemical compound CC1=CC(Br)=C(C)C=N1 CGPIONYVXKQZPW-UHFFFAOYSA-N 0.000 description 1
- BSDGZUDFPKIYQG-UHFFFAOYSA-N 4-bromopyridine Chemical compound BrC1=CC=NC=C1 BSDGZUDFPKIYQG-UHFFFAOYSA-N 0.000 description 1
- SIAVMDKGVRXFAX-UHFFFAOYSA-N 4-carboxyphenylboronic acid Chemical compound OB(O)C1=CC=C(C(O)=O)C=C1 SIAVMDKGVRXFAX-UHFFFAOYSA-N 0.000 description 1
- 102000035038 5-HT1 receptors Human genes 0.000 description 1
- 108091005478 5-HT1 receptors Proteins 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- HHVFVHIUOMMWRN-UHFFFAOYSA-N 5-bromo-1-methylpyridin-2-one Chemical compound CN1C=C(Br)C=CC1=O HHVFVHIUOMMWRN-UHFFFAOYSA-N 0.000 description 1
- NXQRMQIYCWFDGP-UHFFFAOYSA-N 5-fluoro-2,3-dihydro-1h-indole Chemical compound FC1=CC=C2NCCC2=C1 NXQRMQIYCWFDGP-UHFFFAOYSA-N 0.000 description 1
- PUVNBWJBWQUILR-UHFFFAOYSA-N 7-bromo-6-methoxyquinoline Chemical compound C1=CN=C2C=C(Br)C(OC)=CC2=C1 PUVNBWJBWQUILR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101000724725 Homo sapiens 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
- 101000724739 Homo sapiens 5-hydroxytryptamine receptor 1D Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003109 amnesic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- KTLFENNEPHBKJD-UHFFFAOYSA-K benzyl(trimethyl)azanium;tribromide Chemical compound [Br-].[Br-].[Br-].C[N+](C)(C)CC1=CC=CC=C1.C[N+](C)(C)CC1=CC=CC=C1.C[N+](C)(C)CC1=CC=CC=C1 KTLFENNEPHBKJD-UHFFFAOYSA-K 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000011905 homologation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- AZHDFJVTCVTQIZ-UHFFFAOYSA-N methyl 2-(4-bromonaphthalen-1-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OC)=CC=C(Br)C2=C1 AZHDFJVTCVTQIZ-UHFFFAOYSA-N 0.000 description 1
- NSWYFJWAOXYZDF-UHFFFAOYSA-N methyl 4-bromonaphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC=C(Br)C2=C1 NSWYFJWAOXYZDF-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- PMYJAVHDFDKJBS-UHFFFAOYSA-N n-(4-acetyl-2-bromophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(C(C)=O)C=C1Br PMYJAVHDFDKJBS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 201000000484 premenstrual tension Diseases 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000004000 serotonin 1B antagonist Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003555 thioacetals Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9922831.4A GB9922831D0 (en) | 1999-09-25 | 1999-09-25 | Novel compounds |
| GB9922831.4 | 1999-09-25 | ||
| GB0001936.4 | 2000-01-27 | ||
| GB0001936A GB0001936D0 (en) | 2000-01-27 | 2000-01-27 | Novel compounds |
| GB0013873A GB0013873D0 (en) | 2000-06-07 | 2000-06-07 | Novel compounds |
| GB0013873.5 | 2000-06-07 | ||
| PCT/EP2000/009442 WO2001023374A1 (en) | 1999-09-25 | 2000-09-21 | Piperazine derivatives as 5-ht1b antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2385737A1 true CA2385737A1 (en) | 2001-04-05 |
Family
ID=27255501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002385737A Abandoned CA2385737A1 (en) | 1999-09-25 | 2000-09-21 | Piperazine derivatives as 5-ht1b antagonists |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6747030B1 (cs) |
| EP (1) | EP1216239B1 (cs) |
| JP (1) | JP2003510317A (cs) |
| KR (1) | KR20020030126A (cs) |
| CN (1) | CN1190432C (cs) |
| AR (1) | AR029454A1 (cs) |
| AT (1) | ATE259363T1 (cs) |
| AU (1) | AU765020B2 (cs) |
| BR (1) | BR0014279A (cs) |
| CA (1) | CA2385737A1 (cs) |
| CO (1) | CO5200839A1 (cs) |
| CZ (1) | CZ20021038A3 (cs) |
| DE (1) | DE60008262T2 (cs) |
| DK (1) | DK1216239T3 (cs) |
| ES (1) | ES2211624T3 (cs) |
| HK (1) | HK1046909B (cs) |
| HU (1) | HUP0202787A3 (cs) |
| IL (1) | IL148818A0 (cs) |
| MX (1) | MXPA02003175A (cs) |
| MY (1) | MY122391A (cs) |
| NO (1) | NO20021459D0 (cs) |
| NZ (1) | NZ517865A (cs) |
| PE (1) | PE20010641A1 (cs) |
| PL (1) | PL362900A1 (cs) |
| PT (1) | PT1216239E (cs) |
| TR (1) | TR200200795T2 (cs) |
| WO (1) | WO2001023374A1 (cs) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001023374A1 (en) * | 1999-09-25 | 2001-04-05 | Smithkline Beecham P.L.C. | Piperazine derivatives as 5-ht1b antagonists |
| HUP0400651A2 (hu) | 2000-11-07 | 2004-06-28 | Bristol-Myers Squibb Company | Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| US6906192B2 (en) | 2000-11-07 | 2005-06-14 | Bristol Myers Squibb Company | Processes for the preparation of acid derivatives useful as serine protease inhibitors |
| GB0106419D0 (en) | 2001-03-15 | 2001-05-02 | Smithkline Beecham Plc | Novel compounds |
| GB0106586D0 (en) * | 2001-03-16 | 2001-05-09 | Smithkline Beecham Plc | Novel compounds |
| GB0224557D0 (en) * | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| EP1638932A1 (en) * | 2003-06-18 | 2006-03-29 | Pfizer Products Inc. | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams |
| WO2006010629A1 (en) | 2004-07-28 | 2006-02-02 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
| PE20080176A1 (es) | 2006-03-31 | 2008-04-25 | Glaxo Group Ltd | Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs) |
| US8921124B2 (en) | 2006-03-31 | 2014-12-30 | Wako Pure Chemical Industries, Ltd. | Pyrazole-based cyanine dye |
| AU2011289615B2 (en) | 2010-08-10 | 2015-05-07 | Melinta Therapeutics, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| CN102766139B (zh) * | 2012-08-14 | 2014-09-17 | 江苏先声药物研究有限公司 | 阿齐沙坦的多晶型物及其制备方法 |
| EA201591003A1 (ru) | 2013-01-04 | 2015-12-30 | Ремпекс Фармасьютикалз, Инк. | Производные бороновой кислоты и их терапевтическое применение |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN104981239B (zh) | 2013-01-04 | 2019-01-04 | 莱姆派克斯制药公司 | 硼酸衍生物及其治疗用途 |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9687497B1 (en) | 2014-05-05 | 2017-06-27 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| RS59488B1 (sr) | 2014-05-05 | 2019-12-31 | Rempex Pharmaceuticals Inc | Sinteza boronatnih soli i njihove upotrebe |
| US9963467B2 (en) | 2014-05-19 | 2018-05-08 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| MX2016016666A (es) | 2014-07-01 | 2017-08-08 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y usos terapeuticos de los mismos. |
| WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| GB2532990A (en) | 2014-12-05 | 2016-06-08 | Schlumberger Holdings | Corrosion inhibition |
| WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| GB2543498A (en) * | 2015-10-19 | 2017-04-26 | Schlumberger Holdings | Corrosion inhibition |
| PL3478693T3 (pl) | 2016-06-30 | 2021-12-13 | Qpex Biopharma, Inc. | Pochodne kwasu boronowego i ich zastosowania terapeutyczne |
| IL273551B2 (en) | 2017-10-11 | 2024-02-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis |
| AU2019256351B2 (en) | 2018-04-20 | 2024-02-29 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2162792T3 (es) | 1991-09-18 | 2002-01-16 | Glaxo Group Ltd | Derivados de benzanilida como antagonistas de 5-ht1d. |
| EP0716650B1 (en) * | 1993-09-03 | 1999-03-24 | Smithkline Beecham Plc | Indole and indoline derivatives as 5ht1d receptor antagonists |
| JP2001506995A (ja) * | 1996-12-19 | 2001-05-29 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Ｎ−ピペラジン−１−イルフェニル−ベンズアミド誘導体 |
| CA2288172A1 (en) * | 1997-04-18 | 1998-10-29 | Smithkline Beecham P.L.C. | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
| CN1260781A (zh) | 1997-04-18 | 2000-07-19 | 史密丝克莱恩比彻姆有限公司 | 具有综合的5ht1a、5ht1b和5ht1d受体拮抗剂活性的吲哚衍生物 |
| GB9725931D0 (en) * | 1997-12-05 | 1998-02-04 | Smithkline Beecham Plc | Novel compounds |
| WO2001023374A1 (en) * | 1999-09-25 | 2001-04-05 | Smithkline Beecham P.L.C. | Piperazine derivatives as 5-ht1b antagonists |
-
2000
- 2000-09-21 WO PCT/EP2000/009442 patent/WO2001023374A1/en active IP Right Grant
- 2000-09-21 CN CNB008162697A patent/CN1190432C/zh not_active Expired - Fee Related
- 2000-09-21 KR KR1020027003825A patent/KR20020030126A/ko not_active Ceased
- 2000-09-21 TR TR2002/00795T patent/TR200200795T2/xx unknown
- 2000-09-21 BR BR0014279-4A patent/BR0014279A/pt not_active IP Right Cessation
- 2000-09-21 US US10/089,013 patent/US6747030B1/en not_active Expired - Fee Related
- 2000-09-21 DE DE60008262T patent/DE60008262T2/de not_active Expired - Fee Related
- 2000-09-21 HK HK02108463.9A patent/HK1046909B/en not_active IP Right Cessation
- 2000-09-21 CA CA002385737A patent/CA2385737A1/en not_active Abandoned
- 2000-09-21 PT PT00967803T patent/PT1216239E/pt unknown
- 2000-09-21 JP JP2001526526A patent/JP2003510317A/ja active Pending
- 2000-09-21 NZ NZ517865A patent/NZ517865A/en unknown
- 2000-09-21 PL PL00362900A patent/PL362900A1/xx not_active Application Discontinuation
- 2000-09-21 AT AT00967803T patent/ATE259363T1/de not_active IP Right Cessation
- 2000-09-21 AU AU77836/00A patent/AU765020B2/en not_active Ceased
- 2000-09-21 MX MXPA02003175A patent/MXPA02003175A/es active IP Right Grant
- 2000-09-21 DK DK00967803T patent/DK1216239T3/da active
- 2000-09-21 HU HU0202787A patent/HUP0202787A3/hu unknown
- 2000-09-21 IL IL14881800A patent/IL148818A0/xx unknown
- 2000-09-21 ES ES00967803T patent/ES2211624T3/es not_active Expired - Lifetime
- 2000-09-21 EP EP00967803A patent/EP1216239B1/en not_active Expired - Lifetime
- 2000-09-21 CZ CZ20021038A patent/CZ20021038A3/cs unknown
- 2000-09-22 PE PE2000000989A patent/PE20010641A1/es not_active Application Discontinuation
- 2000-09-22 CO CO00072095A patent/CO5200839A1/es not_active Application Discontinuation
- 2000-09-22 AR ARP000104983A patent/AR029454A1/es not_active Application Discontinuation
- 2000-09-22 MY MYPI20004437A patent/MY122391A/en unknown
-
2002
- 2002-03-22 NO NO20021459A patent/NO20021459D0/no not_active Application Discontinuation
-
2004
- 2004-03-17 US US10/802,236 patent/US20040176388A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6747030B1 (en) | 2004-06-08 |
| EP1216239A1 (en) | 2002-06-26 |
| HUP0202787A3 (en) | 2003-12-29 |
| PL362900A1 (en) | 2004-11-02 |
| AU7783600A (en) | 2001-04-30 |
| NZ517865A (en) | 2003-11-28 |
| DE60008262D1 (de) | 2004-03-18 |
| MXPA02003175A (es) | 2002-09-30 |
| NO20021459L (no) | 2002-03-22 |
| ATE259363T1 (de) | 2004-02-15 |
| AU765020B2 (en) | 2003-09-04 |
| ES2211624T3 (es) | 2004-07-16 |
| MY122391A (en) | 2006-04-29 |
| CZ20021038A3 (cs) | 2002-08-14 |
| DK1216239T3 (da) | 2004-06-14 |
| US20040176388A1 (en) | 2004-09-09 |
| KR20020030126A (ko) | 2002-04-22 |
| HK1046909B (en) | 2004-12-03 |
| TR200200795T2 (tr) | 2002-07-22 |
| PE20010641A1 (es) | 2001-07-14 |
| EP1216239B1 (en) | 2004-02-11 |
| CN1190432C (zh) | 2005-02-23 |
| HK1046909A1 (en) | 2003-01-30 |
| AR029454A1 (es) | 2003-07-02 |
| WO2001023374A1 (en) | 2001-04-05 |
| CO5200839A1 (es) | 2002-09-27 |
| BR0014279A (pt) | 2002-05-21 |
| NO20021459D0 (no) | 2002-03-22 |
| CN1399635A (zh) | 2003-02-26 |
| HUP0202787A2 (hu) | 2002-12-28 |
| PT1216239E (pt) | 2004-05-31 |
| JP2003510317A (ja) | 2003-03-18 |
| IL148818A0 (en) | 2002-09-12 |
| DE60008262T2 (de) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2385737A1 (en) | Piperazine derivatives as 5-ht1b antagonists | |
| JP5375824B2 (ja) | アミド化合物 | |
| US6593322B1 (en) | Compounds and methods for modulation of estrogen receptors | |
| JP3328936B2 (ja) | ５ｈｔ１ｄレセプター拮抗薬用インドールおよびインドリン誘導体 | |
| EP1414442A1 (en) | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | |
| WO2005087746A1 (en) | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | |
| JPH05230059A (ja) | ベンゾジオキサン誘導体 | |
| JP2008516922A (ja) | ヒスタミン受容体リガンドとしてのピロリジン誘導体 | |
| JP2005516951A (ja) | 尿素誘導体およびバニロイド受容体アンタゴニストとしてのその使用 | |
| JP2010509266A (ja) | ５−ｈｔ６阻害剤としてのアリールスルホニルピロリジン | |
| MX2013001202A (es) | Compuestos de piridina de anillo fusionado. | |
| JP2004527516A (ja) | ピペラジン誘導体、それらの製造方法および治療における使用（５ｈｔ１ｂ受容体活性） | |
| JP2008502644A (ja) | ヒスタミンｈ３アンタゴニストとしての３−シクロアルキルベンズアゼピン | |
| US20040053956A1 (en) | Isoquinoline derivatives useful in the treatment of cns disorders | |
| CA2642619A1 (en) | Pyrrole derivative or salt thereof | |
| AU655365B2 (en) | Tetrazolyl-(phenoxy and phenoxyalkyl)-piperidinylpyridazines as antiviral agents | |
| JP4975817B2 (ja) | アリールピペラジン誘導体およびその使用 | |
| JP2004529124A (ja) | ５−ｈｔ１ｂリガンドとしてのピペラジン誘導体およびその使用 | |
| HU211690A9 (hu) | Az átmeneti oltalom az 1—18. igénypontokra vonatkozik. | |
| HU211665A9 (hu) | Az átmeneti oltalom az 1-19. igénypontokra vonatkozik. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |